The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I):

##STR00001##

wherein R.sup.1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R.sup.2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH wherein the ionic polymer is a homopolymer or a random copolymer, wherein the repetitive unit of formula (I) in a random copolymer comprises (dimethylamino)ethyl methacrylate, wherein the molar proportion of (dimethylamino)ethyl methacrylate repetitive units to the total number of repetitive units in a random copolymer is greater than 50%, and wherein the at least one hydrophobic active agent has a molecular weight of from 100 to 1500 g/mol; a complex for use in a method of medical treatment; a pharmaceutical composition; and a method of preparing a complex or pharmaceutical composition according to the invention which method comprises the steps of:

(a) dissolving the hydrophobic active agent and the ionic polymer in one or more non-aqueous solvents to form the complex wherein the one or more non-aqueous solvents are miscible with water; and

(b) progressively replacing the one or more non-aqueous solvents with water.

Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.

The present invention includes a pharmaceutical composition and method of making and using comprising one or more thyroid hormones or analogs thereof, wherein a first portion of thyroid hormone is formulated for modified release and a second portion of the one or more thyroid hormones is formulated for modified release, wherein the combination of the first and second portion are provided in an amount effective to treat hypothyroidism.

Zwitterionic phosphatidylserine (ZPS) monomers, ZPS polymers and ZPS copolymers, methods for making the ZPS monomers, ZPS polymers, and ZPS copolymers, compositions and materials that include ZPS polymers and ZPS copolymers, and methods for using the ZPS monomers, ZPS polymers, and ZPS copolymers.

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidateion exchange resin complex, a barrier coated methylphenidateion exchange resin complexmatrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine, as well as an extended release and uptake of nicotine. The invention further describes suitable manufacturing processes for such chewing gum formulations, as well as the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.